ABUS vs SPGI · P/E 5.4, rev $6.2M vs P/E 27, rev $15.34B
Arbutus Biopharma Corp (ABUS) versus S&P Global Inc (SPGI) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
S&P Global Inc (SPGI) is a financial data & stock exchanges company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported SPGI revenue for 2025-12-31 was $15.34B. Net income was $4.47B. Revenue was up 7.9% from 2024-12-31 to 2025-12-31. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. SPGI currently screens at market cap $127.50B and trailing P/E 27.2.
Not investment advice. Open the ABUS and SPGI stock pages for the full models.
Not investment advice.